Omnicell (NASDAQ:OMCL) Shares Down 4.1% - Time to Sell?

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) traded down 4.1% during trading on Monday . The stock traded as low as $27.21 and last traded at $27.51. 91,701 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 561,881 shares. The stock had previously closed at $28.69.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research report on Friday, May 23rd. Benchmark lowered their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. JPMorgan Chase & Co. lowered their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, March 20th. Finally, Wells Fargo & Company reissued an "overweight" rating and issued a $37.00 price objective (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Omnicell currently has a consensus rating of "Moderate Buy" and an average price target of $44.83.

Omnicell Stock Performance

The stock has a market cap of $1.30 billion, a P/E ratio of 59.95 and a beta of 0.76. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.38. The company's 50 day moving average price is $28.99 and its 200-day moving average price is $34.62.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. The company had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The business's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.03 EPS. Equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Omnicell by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock worth $247,628,000 after buying an additional 28,573 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Omnicell by 10.1% during the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock valued at $58,745,000 after acquiring an additional 154,038 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after purchasing an additional 394,820 shares during the last quarter. Lazard Asset Management LLC grew its stake in shares of Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after purchasing an additional 737,536 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its position in Omnicell by 4.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock valued at $53,290,000 after purchasing an additional 56,117 shares during the last quarter. Institutional investors own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.